SAN DIEGO, Sep 7, 2023 – Coastar Therapeutics Inc., a biotech company developing a delivery technology for cancer immunotherapy and gene therapy, announced that it will be presenting at two biotech conferences – the BioFuture on October 4-5, 2023 in New York and the BIO Investor Conference on Oct 17-18 in San Francisco. 

Coastar Therapeutics has developed ENHEnS^TM, an innovative cell membrane coating technology platform that enables a wide range of biological payloads to avoid immune clearance and be successfully delivered to disease sites. The technology will lead to increased efficacy, reduced toxicity, lower cost and more applications in cancers and other diseases.

“Our technology will make a profound impact on cancer and rare disease treatments that utilize biologics as therapeutic agents. In addition to its higher efficacy and wider applications, it is also highly scalable. It will lower the cost of treatment and help millions of patients worldwide achieve better clinical outcome ” said Eddie Y. Chung, CEO of Coastar Therapeutics.

“Coastar is making tremendous progress working with our biopharma partners to deliver their drugs”, said Han L. Lim, Chief Science Officer of Coastar Therapeutics. “The versatility of our platform technology means it can help various drugs achieve higher efficacy and reduce safety risk by optimizing the delivery vehicle with each individual drug. We look forward to welcoming more partners on board our platform.”

“We are excited about the BioFuture and Bio Investor Conferences! The biotech market has been looking for effective biologic delivery technology for a long time, and we believe timing is right for our technology to benefit the industry and ultimately the patients out there.” said Chongyang Luo, Chief Operating Officer of Coastar.

ABOUT COASTAR THERAPEUTICS

Coastar Therapeutics Inc., is a San Diego based company developing biological payload delivery technologies for cancer and gene therapies. The company’s proprietary ENHEnS^TM technology can coat cell membranes on biological payloads to help them evade recognition and clearance by the immune system and be successfully delivered to tumor or other disease sites. The company is working with a number of partners to help deliver their drugs.